Peptide Injection Frequency: How Often Should You Inject Peptides?

Why Injection Frequency Is Not One-Size-Fits-All

The right injection schedule is dictated by three pharmacological variables: half-life, receptor-saturation kinetics, and the physiological rhythm you are trying to mimic. Semaglutide has a plasma half-life of roughly 165 hours, which is why once-weekly dosing maintains steady-state concentration. Ipamorelin has a half-life closer to 2 hours and must be dosed in short pulses to replicate the natural growth hormone (GH) surges the pituitary releases four to six times per day.

Endogenous GH secretion is pulsatile, not tonic. Administering a GH secretagogue at the wrong time, or too continuously, can blunt the pituitary's own response through receptor downregulation. A 2021 review published in Growth Hormone and IGF Research confirmed that continuous GH-releasing peptide exposure suppresses endogenous GHRH signaling within days, while pulsatile dosing preserves the hypothalamic-pituitary axis sensitivity [1].

Tissue-targeting peptides such as BPC-157 follow different rules. Their effect appears concentration-dependent rather than pulsatile, and twice-daily dosing at 250-500 mcg per injection is the schedule used in most preclinical models showing tendon, mucosal, and nerve repair [2].

The HealthRX clinical team uses a three-category framework to set injection frequency at intake:

1. Receptor-pulsatile peptides (ipamorelin, GHRP-6, GHRP-2): dose 2-3x daily, at least one dose 30-60 minutes before sleep to align with nocturnal GH surge.
2. Long-acting secretagogues (CJC-1295 with DAC, tesamorelin): dose 1-2x per week to exploit the extended half-life without saturating receptors.
3. Tissue-repair and signaling peptides (BPC-157, TB-500, PT-141): dose based on indication, ranging from once daily to on-demand.

FDA-Approved Peptides: Schedules That Have Regulatory Backing

FDA-approved peptides have clearly defined dosing schedules from Phase III trials. These are the schedules with the strongest evidence base.

Semaglutide (Ozempic, Wegovy): The FDA-approved label for Wegovy specifies 0.25 mg subcutaneously once weekly for four weeks, then 0.5 mg weekly for four weeks, continuing escalation until the 2.4 mg maintenance dose is reached at week 16-20. In STEP-1 (N=1,961), this once-weekly schedule produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo (P<0.001) [3]. Missing even one weekly injection causes measurable trough-level drops that may increase nausea on the next dose.

Tesamorelin (Egrifta SV): Approved at 2 mg subcutaneously once daily for HIV-associated lipodystrophy. A 26-week randomized controlled trial (N=412) showed 15.2% reduction in visceral adipose tissue versus placebo, with effects requiring continuous daily administration [4].

Bremelanotide / PT-141 (Vyleesi): Approved for hypoactive sexual desire disorder in premenopausal women at 1.75 mg subcutaneously 45 minutes before anticipated sexual activity. The label caps use at one dose per 24 hours and no more than once per week due to transient blood pressure effects [5].

The FDA's guidance document on peptide drug products states: "Peptide drug substances are subject to the same safety, effectiveness, and current good manufacturing practice requirements as any other drug substance." [6]

CJC-1295 and Ipamorelin: The Most Common Compounded Stack

CJC-1295 with DAC combined with ipamorelin is the most frequently prescribed compounded peptide stack in US longevity clinics. Each component has a distinct half-life that requires a different injection schedule, and they are often drawn into the same syringe for a single daily or twice-weekly injection depending on which CJC-1295 formulation is used.

CJC-1295 with DAC: The Drug Affinity Complex (DAC) modification covalently binds CJC-1295 to albumin in the bloodstream, extending the half-life to approximately 8 days. This allows once-weekly or twice-weekly subcutaneous dosing at 1-2 mg per injection. A 2006 Phase II trial published in the Journal of Clinical Endocrinology and Metabolism (N=65) showed that a single 2 mg injection of CJC-1295 with DAC produced GH increases sustained for 6 days and IGF-1 elevations lasting up to 14 days [7].

CJC-1295 without DAC (also called Modified GRF 1-29): Without the albumin-binding modification, half-life drops to approximately 30 minutes. This form requires 2-3 daily injections and is always combined with ipamorelin in the same syringe.

Ipamorelin alone: Typical doses range from 200-300 mcg per injection, given 2-3 times daily. The timing that produces the largest GH pulse is 30-60 minutes before sleep, because it amplifies the natural nocturnal surge. Morning and pre-workout doses are secondary windows.

A practical clinical note: the CJC-1295/ipamorelin stack produces mean IGF-1 increases of 30-40% above baseline in most adults over 40. Checking IGF-1 at baseline and at 8 weeks lets the prescribing clinician confirm response without relying on GH levels, which fluctuate hour-to-hour.

BPC-157: Dosing Windows for Tissue Repair

BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide derived from a human gastric protein. It is not FDA-approved as a drug and is classified as a research compound in the United States. Preclinical data from rodent models show accelerated healing of tendons, ligaments, gut mucosa, and peripheral nerves [2].

The dose used in most published rodent studies is 10 mcg/kg/day. Scaled to a 75 kg adult, that approximates 750 mcg/day. Most compounding pharmacy protocols divide this into two daily injections of 250-500 mcg each, injected subcutaneously near the site of injury when local effect is desired, or in the abdomen when systemic effect is the goal.

Cycles typically run 4-12 weeks. There is no published long-term safety data in humans at these doses, and the FDA issued a safety alert in 2024 noting that BPC-157 and other novel peptides obtained outside of licensed compounding pharmacies may contain impurities [8].

GHRP-6 and GHRP-2: Older Secretagogues Still in Circulation

GHRP-6 (growth hormone-releasing peptide 6) and GHRP-2 are earlier-generation secretagogues with shorter half-lives than ipamorelin and a higher incidence of cortisol and prolactin co-stimulation. Both require three injections daily at 100-300 mcg per injection.

The cortisol spike with GHRP-6 is pronounced enough to be measurable: a study in healthy men showed a 35% rise in serum cortisol 15 minutes post-injection at 1 mcg/kg [9]. This is one reason ipamorelin has largely replaced GHRP-6 in clinical practice. Ipamorelin produces negligible cortisol or prolactin changes at standard doses, making it a cleaner option for people concerned about adrenal load.

Sermorelin: The Closest to Natural GHRH

Sermorelin acetate is a 29-amino-acid fragment of endogenous GHRH. Because it mimics the body's own releasing hormone, it preserves natural feedback mechanisms better than many other secretagogues. The standard protocol is 0.2-0.3 mg subcutaneously once daily at bedtime, timed to amplify the nocturnal GH pulse.

The Endocrine Society's clinical practice guideline on adult GH deficiency states that GHRH-based therapies "should be timed to coincide with endogenous pulsatile secretion patterns where possible." [10] Sermorelin's short half-life (under 10 minutes in plasma) means the pituitary stimulus is brief and physiological, reducing the receptor desensitization seen with continuous GHRP exposure.

Response monitoring: IGF-1 should be checked at baseline and at 3 months. Target IGF-1 is the mid-to-upper tertile of the age-adjusted reference range, not supraphysiological levels.

Are Peptides Legal in the United States?

Legal status in the US separates into three categories, and confusing them can have real consequences.

FDA-approved peptides include semaglutide, liraglutide, tesamorelin, bremelanotide, oxytocin, vasopressin analogs, and insulin. These are fully legal with a valid prescription.

Compounded peptides occupy a grayer legal space. The FDA's 503A compounding framework permits licensed pharmacies to compound drug substances that appear on specific FDA lists. In 2024, the FDA removed semaglutide from the drug shortage list, effectively prohibiting most 503A compounding of semaglutide. BPC-157, CJC-1295, and ipamorelin are not on any FDA-approved drug substance list for 503A compounding, which means compounding pharmacies technically cannot dispense them for human use. The FDA has sent warning letters to pharmacies dispensing these compounds [8].

Research-only peptides such as those sold labeled "for research use only, not for human use" are sold without a prescription. Purchasing and injecting them bypasses both prescription requirements and manufacturing quality controls. Standard GMP testing does not apply, and contamination risk is real.

The bottom line: if you are in the US and working with a licensed telehealth or in-person provider, confirm that any compounded peptide comes from an FDA-registered 503B outsourcing facility, which has GMP standards, or is an FDA-approved product.

Can Peptides Show Up on a Drug Test?

The answer depends entirely on which peptide and which test. Standard workplace urine immunoassay panels test for opioids, amphetamines, cannabinoids, cocaine metabolites, benzodiazepines, and PCP. None of the peptides discussed in this article appear on those panels.

Competitive sports testing is a different situation. WADA's Prohibited List includes GH secretagogues, GH-releasing peptides, and growth hormone-releasing factors explicitly under section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) [11]. Ipamorelin, CJC-1295, GHRP-2, GHRP-6, sermorelin, and tesamorelin are all detectable with high-resolution mass spectrometry in urine and blood. Detection windows range from 24-72 hours for short-half-life peptides to several days for longer-acting forms.

Semaglutide is not on the 2024 or 2025 WADA Prohibited List, though WADA has flagged GLP-1 receptor agonists for monitoring. PT-141 / bremelanotide is also not currently prohibited by WADA.

Athletes governed by USADA, NADA, or any WADA-signatory organization should check the specific Prohibited List for their sport year and consult their national anti-doping organization before starting any peptide.

Peptide Injection Pain: Causes and Reduction Strategies

Injection pain with peptides is common but usually mild and manageable. The primary causes are pH mismatch, bacteriostatic water concentration, injection speed, and tissue-site selection.

Most compounded peptides are reconstituted with bacteriostatic water (pH 4.5-5.5) or sterile water. Human subcutaneous tissue has a pH of 7.35-7.45. The greater the pH mismatch, the sharper the sting. Some pharmacies buffer reconstituted peptides toward a more neutral pH, which reduces discomfort noticeably.

Practical steps that reduce injection pain:

• Let the reconstituted vial reach room temperature before injecting. Cold solutions cause more discomfort.
• Use 27-29 gauge, 0.5-inch insulin-type needles for subcutaneous dosing. Larger gauges increase tissue trauma.
• Inject slowly over 10-15 seconds. Rapid bolus injection into subcutaneous tissue stretches the space faster than it can accommodate.
• Rotate sites. The abdomen (at least 2 inches from the navel), lateral thighs, and flanks are all acceptable subcutaneous locations. Repeated injections into the same 1 cm area cause lipohypertrophy and increase pain on subsequent injections.
• Apply brief pressure (not rubbing) after withdrawal.

Post-injection nodules lasting 24-48 hours are usually sterile inflammatory reactions to the reconstitution solution rather than infection. A nodule that is warm, expanding, and present after 72 hours should be evaluated by a clinician.

Can Peptides Be Taken Orally?

Most injectable peptides are nearly destroyed by oral administration. The gastrointestinal tract is designed to break down dietary proteins and peptides into individual amino acids. Proteases including pepsin, trypsin, and chymotrypsin cleave peptide bonds within minutes of ingestion, and the intestinal epithelium is largely impermeable to intact peptide sequences longer than 3-5 amino acids [12].

Oral semaglutide (Rybelsus) is the most prominent exception, and it required a proprietary absorption enhancer (SNAC: sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) to achieve even 1% bioavailability. The PIONEER-1 trial (N=703) showed that 14 mg oral semaglutide once daily reduced HbA1c by 1.4 percentage points versus 0.1 percentage point for placebo over 26 weeks [13]. That result required specific administration instructions: taken on an empty stomach with no more than 4 oz of water, followed by a 30-minute fast.

Collagen peptides taken orally are a legitimate exception in a different sense. Collagen hydrolysates are enzymatically pre-digested to small di- and tripeptides that can cross the intestinal epithelium. A 2021 randomized controlled trial (N=120) found that 10 g/day of hydrolyzed collagen over 12 weeks improved skin elasticity versus placebo (P<0.05) [14]. These are food supplements, not drugs, and their mechanism differs completely from injectable peptide pharmaceuticals.

Intranasal delivery is another alternative for select peptides. PT-141 was originally developed as a nasal spray; the FDA ultimately approved the subcutaneous formulation because nasal bioavailability was variable. Oxytocin nasal spray achieves roughly 1% of plasma levels compared to IV oxytocin, but still produces measurable central nervous system effects due to direct olfactory-to-CNS transport [15].

Monitoring and Adjusting Your Injection Schedule

The injection schedule should be treated as a starting point, not a fixed endpoint. The HealthRX medical team recommends the following monitoring cadence for patients on compounded GH secretagogue stacks:

• Baseline labs before starting: IGF-1, fasting glucose, HbA1c, fasting insulin, comprehensive metabolic panel.
• 8-week check-in: Repeat IGF-1 and fasting glucose. If IGF-1 has not risen by at least 20% above baseline in a patient with confirmed adult-onset GH decline, reassess peptide quality, dosing technique, and timing.
• 3-month labs: Full metabolic panel plus IGF-1. If IGF-1 exceeds the age-adjusted upper limit of normal (typically above 300 ng/mL in adults over 40), reduce dose or frequency before continuing.
• Ongoing: Annual cancer screening is advisable for any patient on long-term GH axis stimulation, because elevated IGF-1 is associated with increased proliferative signaling in certain cancers [16].

The Endocrine Society notes: "IGF-1 concentrations should be maintained within the age- and sex-specific reference range; supraphysiologic levels warrant dose reduction." [10]

Patients who plateau after 3-6 months on a continuous schedule often respond better after a 4-6 week off-cycle period. Receptor sensitivity tends to recover during breaks, and resuming at a slightly lower dose frequently restores the original response.